UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 26, 2024
Elevai Labs Inc. |
(Exact name of registrant as specified in its charter) |
Delaware | 001-41875 | 85-1399981 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
c/o 120 Newport Center Drive, Ste. 250 Newport Beach, CA | 92660 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (866) 794-4940
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4©) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.0001 par value | ELAB | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On August 26, 2024, Elevai Labs Inc. (the “Company”) issued a press release announcing that Elevai Skincare Inc., a subsidiary of the Company, completed a clinical study examining the effectiveness of Elevai enfinity™ exosomes on facial appearance. The study assessed the use of twice-daily Elevai enfinity™, a topical exosome product, on 29 study participants over a 12-week period, to determine the efficacy on facial appearance, including measurements like facial firmness, skin tone, wrinkles and smoothness. The study investigated healthy subjects between 40-70 years of age with mild to moderate facial photoaging and sensitive skin. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable. The Company aims to publish the full study results in the near future. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
Exhibit No. | Description | |
99.1 | Press Release of Elevai Labs, Inc. dated as of August 26, 2024. | |
104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 26, 2024
Elevai Labs, Inc. | ||
By: | /s/ Graydon Bensler | |
Name: | Graydon Bensler | |
Title: | Chief Executive Officer and Chief Financial Officer and Director |